4/A: Haemonetics Executive Amends Equity Award Filing, Correcting RSU and Option Grants

Haemonetics Corp's EVP and General Counsel, Michelle L. Basil, filed an amended SEC Form 4 to correct previously reported restricted stock unit and stock option awards.

Summary

• Michelle L. Basil, Executive Vice President and General Counsel of Haemonetics Corp (HAE), filed a Form 4/A to amend a previous filing regarding her equity awards.
• The amendment corrects the number of Restricted Stock Units (RSUs) awarded on May 16, 2025, from an incorrectly reported 5,689 to the correct amount of 6,755, representing a net increase of 1,066 RSUs.
• The RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan and vest in three equal annual installments starting on the first anniversary of the grant date.
• The filing also corrects the number of non-qualified stock options awarded on May 16, 2025, from an incorrectly reported 12,317 to the correct amount of 14,626, a net increase of 2,309 options.
• These stock options have an exercise price of $70.31 and expire on May 16, 2032, vesting in annual increments of 25% beginning on the first anniversary of the grant date.
• Following these corrected transactions, Ms. Basil beneficially owns 35,233 shares of common stock, which includes unvested RSUs previously reported, and 14,626 non-qualified stock options.
• The corrected amounts will be reflected in future filings by the reporting person.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it is a factual correction of previously reported equity awards, not an announcement of financial performance or strategic changes.

Positives

• The company is transparent in correcting errors in its SEC filings, demonstrating adherence to regulatory requirements.
• Increased equity awards for a key executive (EVP and General Counsel) could align management incentives with shareholder interests.

Negatives

• The need for an amendment indicates an initial error in reporting, which could suggest minor internal control issues in data accuracy, though this appears to be a clerical correction.

Risks

• No specific risks related to company operations or financial health were mentioned in this filing, which is solely focused on executive compensation correction.

Future Outlook

The document states that the corrected amounts of RSUs and options will be reflected in future filings by the reporting person.

Industry Context

This filing is a routine amendment to an executive's equity compensation report and does not provide information relevant to broader industry trends or competitive dynamics within the medical technology or blood management solutions sector.

Stakeholder Impact

• Shareholders: Provides accurate information regarding executive equity compensation, ensuring transparency.
• Management/Employees: Directly impacts the reporting executive's equity holdings and ensures compliance with disclosure requirements.

Next Steps

• The corrected amounts of RSUs and options will be reflected in future filings by the reporting person.

Key Dates

Keywords

Haemonetics Corp, HAE, SEC Form 4/A, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Equity Awards, Insider Trading Report, Amendment